| Literature DB >> 35918116 |
Sarah Blagden1,2, Kathryn Newell3,2, Nareh Ghazarians3, Sabrena Sulaiman3, Lucy Tunn3, Michael Odumala3, Rachel Isba3, Rhiannon Edge3.
Abstract
OBJECTIVE: To identify and analyse the interventions delivered opportunistically in secondary or tertiary medical settings, focused on improving routine vaccination uptake in children and young people.Entities:
Keywords: Health policy; PUBLIC HEALTH; Paediatric infectious disease & immunisation
Mesh:
Year: 2022 PMID: 35918116 PMCID: PMC9351315 DOI: 10.1136/bmjopen-2022-061749
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.
General characteristics of the included studies and their associated interventions
| Characteristic (reference numbers of the included papers) | Frequency, n (%) |
| Clinical setting* | |
| Paediatric inpatient wards | 16 (30.2) |
| Antenatal/neonatal setting | 14 (26.4) |
| Emergency department (ED) | 9 (17.0) |
| Paediatric inpatient wards and outpatient clinics | 8 (15.1) |
| Paediatric outpatient clinics | 6 (11.3) |
| Type of hospital | |
| Tertiary care paediatric hospital | 23 (43.4) |
| Number of sites | |
| Single centre | 41 (77.4) |
| Multicentre | 8 (15.1) |
| Two centres | 4 (7.5) |
| Target immunisation(s) | |
| All due/overdue vaccinations | 20 (37.7) |
| Influenza | 17 (32.1) |
| All upcoming vaccinations (for neonates/infants) | 5 (9.4) |
| Hepatitis B | 5 (9.4) |
| BCG | 2 (3.8) |
| Measles, mumps and rubella | 2 (3.8) |
| ‘Voluntary’ vaccination schedule† | 2 (3.8) |
| Country | |
| USA | 26 (49.1) |
| Australia | 10 (18.9) |
| UK | 4 (7.5) |
| New Zealand | 2 (3.8) |
| Japan | 2 (3.8) |
| Canada | 2 (3.8) |
| South Africa | 1 (1.9) |
| Ireland | 1 (1.9) |
| Bangladesh | 1 (1.9) |
| Nepal | 1 (1.9) |
| India | 1 (1.9) |
| Italy | 1 (1.9) |
| Switzerland | 1 (1.9) |
| Intervention population | |
| Age group‡ | |
|
Includes older children (up to 15–21 years old depending on study) | 22 (41.5) |
|
Preschool and younger school-age children only | 16 (30.2) |
|
Neonates/under 1s only (±pregnant women) | 15 (28.3) |
|
Family members of child also offered vaccination | 4 (7.5) |
| Risk category for vaccine preventable disease(s) of interest | |
|
All children (low risk and high risk) | 42 (79.2) |
|
High risk due to underlying health problem(s)/maternal risk factors | 11 (20.8) |
| Study design | |
| Quality improvement project | 10 (18.9) |
| Clinical audit/service evaluation | 9 (17.0) |
| Cross-sectional study including description of intervention | 8 (15.1) |
| Intervention study | 7 (13.2) |
| Randomised controlled trial | 6 (11.3) |
| Cohort study | 5 (9.4) |
| Retrospective case note review | 5 (9.4) |
| Pilot study | 3 (5.7) |
| Aspects of intervention§ | |
| Offer of pre-discharge vaccination at the secondary/tertiary care setting | 45 (85.9) |
| Patient/family education | 20 (37.7) |
| Extra staff/funding involved in delivering the intervention | 18 (34.0) |
| Training, education and/or promotional materials for staff | 17 (32.1) |
| Multidisciplinary approach to leadership and delivery incorporating medical, nursing and pharmacy colleagues | 12 (22.6) |
| Automatic vaccine ordering/in-built order sets | 8 (15.1) |
| Ongoing feedback to staff regarding the success/uptake of the intervention | 6 (11.3) |
| Collaboration with other external organisations | 4 (7.5) |
| Method of screening vaccination eligibility¶ | |
| Patient/parental recall | 16 (30.2) |
| Handheld written record/immunisation card | 12 (22.6) |
| A local electronic clinical system that alerts staff of eligible patients | 11 (20.8) |
| Checking against national/regional immunisation registry | 9 (17.0) |
| Checking with primary care provider | 2 (3.8) |
| Not required as universal vaccination offer | 13 (24.5) |
*1 study included both ED and inpatient wards.
†In Japan, the vaccination schedule is subdivided into ‘routine’ and ‘voluntary’ vaccinations.88
‡Total does not equal 53 (100%) due to studies also including family members.
§Total does not equal 53 (100%) due to interventions containing multiple components.
¶Total does not equal 53 (100%) as some studies used more than one method.
Ranges of administration of vaccination among eligible patients across the included studies by setting and target vaccination
| Setting | Target vaccination (reference numbers of the included papers) | ||
| Measles, mumps and rubella | Influenza | All due/overdue | |
| Emergency department | 35%–41% | 8.8%–57% | 24.0%–75.0% |
| Inpatients | – | 31.0%–69.1% | 3.4%–80.0% |
| Outpatients | – | 8.0%–90.3% | 53.6%–84.6% |
| Inpatients and outpatients | – | 49.7%–87.4% | |
|
|
|
| |
| Neonatal/antenatal | 80%–85% | 72.52%†–100% | 91.3%–96.0% |
*Combined as there was only one study conducted exclusively in outpatients.
†Mercier et al reported 30% uptake of neonatal hepatitis B vaccination but this coincided with the phasing out of this policy and the introduction of hexavalent vaccination containing hepatitis B at 2, 4 and 6 months and is not included in the range.
Summary of included studies detailing sustained coverage outcomes beyond the initial timeframe of the intervention
| Study (target vaccination) | Baseline coverage | Postintervention coverage | Sustained coverage: timepoint 1 | Sustained coverage: timepoint 2 |
| Muehleisen |
Intervention group=54% Control group=49% | Patients with ≥1 catch-up immunisation within 1 month: Intervention group=27%. Control group=8% (p<0.001) | Patients with ≥1 catch-up immunisation within 9 months: Intervention group=45% Control group=35% (p>0.2)* | – |
| Szilagyi | 64% | Fully immunised for age at 1 day: Manhattan ED=75% Bronx ED=71% | Fully immunised for age at 6 months: Manhattan ED=66% Bronx ED=54% | – |
| Lemaitre | Not applicable (neonates) | Complete vaccine status at 3 months: Experimental group=91.3% Control group=88.1% | Complete vaccine status at 13 months: Experimental group=66.2% Control group=59.5% | Complete vaccine status at 24 months: Experimental group=79.4% Control group=74.3% |
| Kushner | Not applicable (neonates) | Birth dose of hepatitis B vaccination=100% | Dose 2 (1–2 months)=81% | Dose 3 (6–18 months)=74% |
*Exact p value not provided.
ED, emergency department.